Neumora Therapeutics Outlines 2026 Pipeline Strategy with Multiple Clinical Readouts Expected
核心洞察
Neumora Therapeutics announced key 2026 milestones including joint topline readouts for KOASTAL-2 and -3 studies of navacaprant in major depressive disorder (搜索) expected in the second quarter.
The company plans to initiate Phase 1 clinical trials for NMRA-215 (搜索), a brain-penetrant NLRP3 (搜索) inhibitor, for obesity (搜索) treatment in the first half of 2026 following class-leading preclinical data.
NMRA-511 demonstrated clinically meaningful effects on AD agitation in Phase 1b studies, with the company advancing its M4 PAM franchise programs NMRA-898 (搜索) and NMRA-861 (搜索).
Neumora Therapeutics, Inc. (Nasdaq: NMRA) announced its 2026 pipeline strategy and anticipated milestones, positioning the clinical-stage biopharmaceutical company for what CEO Paul L. Berns described as a "catalyst-rich period" that could meaningfully shape the company's future and treatment options for underserved neurological diseases.
The Watertown, Massachusetts-based company outlined multiple clinical data readouts expected throughout 2026, presenting opportunities for substantial value creation across its neuroscience portfolio targeting novel mechanisms of action.
Navacaprant Phase 3 Program Advances
Neumora plans to increase enrollment in its KOASTAL studies, targeting up to 25 percent enrollment beyond the original target of 332 participants, as permitted by study protocols. The company expects a joint topline data readout for both KOASTAL-2 and KOASTAL-3 in the second quarter of 2026, believing this approach optimizes assessment of navacaprant efficacy in major depressive disorder (搜索).
NLRP3 Inhibitor Enters Clinical Development
Following class-leading preclinical data from diet-induced obesity (搜索) models, Neumora expects to initiate a clinical program evaluating NMRA-215 (搜索) monotherapy and combination therapy for obesity treatment in the first half of 2026. The highly brain-penetrant NLRP3 (搜索) inhibitor represents a prioritized program for the company, with weight loss data expected around the end of 2026.
Positive Results Drive NMRA-511 Advancement
In January 2026, NMRA-511, an oral, highly potent, brain-penetrant and selective antagonist of the vasopressin 1a receptor (搜索) (V1aR), met the goal of its Phase 1b study by demonstrating a clinically meaningful effect size in people with Alzheimer's disease (搜索) agitation. The study showed NMRA-511 demonstrated a clinically meaningful effect on CMAI total score while maintaining a favorable tolerability and safety profile with no reports of somnolence or sedation.
M4 PAM Franchise Expansion
Neumora continues progressing Phase 1 clinical studies for NMRA-898 (搜索) and NMRA-861 (搜索) as part of its M4 Positive Allosteric Modulator (PAM) franchise expansion. The company expects to provide a comprehensive M4 franchise update in mid-2026, including potentially advancing development of one or both programs.
Strong Financial Foundation
The company reported a strong financial position, with cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027. This financial runway provides stability as the company advances multiple programs through clinical development.
"2025 was a productive and strategically important year for Neumora, as we advanced our pipeline of novel mechanism therapies, prioritized obesity (搜索) as the lead indication for our highly brain-penetrant NLRP3 (搜索) inhibitor, NMRA-215 (搜索), expanded our M4 PAM franchise with two new programs in clinical development, progressed the Phase 3 program for navacaprant, and produced compelling data for NMRA-511 – all while continuing to strengthen our financial foundation," said Paul L. Berns, co-founder, chairman and chief executive officer of Neumora.
Neumora's therapeutic pipeline currently consists of seven neuroscience programs targeting novel mechanisms of action for underserved neuropsychiatric disorders and neurodegenerative diseases. The company's mission focuses on redefining neuroscience drug development by bringing forward next-generation therapies that offer improved treatment outcomes and quality of life for patients with brain diseases.